Premium
18 F‐fluorodeoxyglucose–positron emission tomography in evaluation of primary cutaneous lymphoma
Author(s) -
Kumar R.,
Xiu Y.,
Zhuang H.M.,
Alavi A.
Publication year - 2006
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.2006.07367.x
Subject(s) - positron emission tomography , medicine , nuclear medicine , fluorodeoxyglucose , lymphoma , positron , positron emission tomography computed tomography , positron emission , tomography , radiology , physics , pathology , nuclear physics , electron
Summary Background The diagnosis of primary cutaneous lymphoma (PCL) is currently based on clinical and histological findings and/or relatively invasive procedures such as bone marrow and fine‐needle lymph node biopsies. Although computed tomography (CT) is a noninvasive imaging modality that is widely used for staging in patients with lymphoma, it cannot provide information about malignant cutaneous lesions. Objectives To investigate the usefulness of 18 F‐fluorodeoxyglucose (FDG)–positron emission tomography (PET) in the management of PCL. Methods We retrospectively analysed 31 FDG‐PET studies in 19 patients with PCL [15 T‐cell non‐Hodgkin lymphoma (NHL) and four B‐cell NHL]. There were 10 men and nine women (age range 23–84 years, mean ± SD 54 ± 16). Eleven FDG‐PET studies were performed for initial staging and 20 FDG‐PET studies were performed for restaging following therapy. Results of FDG‐PET were compared with those of CT. Clinical parameters and/or biopsy results of lesions served as reference for the accuracy of PET and CT in evaluating local and metastatic lesions. Results For the initial staging, FDG‐PET had a sensitivity of 82% for the evaluation of local disease and 80% for the detection of distant metastasis. The corresponding values for CT were 55% and 100%, respectively. For restaging of cutaneous lymphoma, FDG‐PET had a sensitivity of 86% and specificity of 92% for local recurrence/residual disease and a sensitivity of 100% and specificity of 100% for distant metastasis. The corresponding values for CT were 50% and 83% for local recurrence/residual disease and 100% and 67% for distant metastasis. Conclusions FDG‐PET has a potential value for initial staging and restaging following therapy in patients with PCL. FDG‐PET has higher diagnostic value than CT in the detection both of local disease and distant metastasis.